Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of LY2605541 Dosing Schedules in Type 1 Diabetes
NCT01792284Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2013
- Primary completion
- Apr 2014
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 3 trial of insulin peglispro in type 1 diabetes mellitus (T1D), sponsored by Eli Lilly and Company. Started Feb 2013; status: completed.
02
Drugs
insulin peglispro
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT01792284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01792284.